Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Given gets US nod for 14-frame PillCam:

This article was originally published in Clinica

Executive Summary

The US FDA has cleared for sale a 14-frame version of Given Imaging's ingestible PillCam ESO video capsule for visualising the oesophageal mucosa. As part of the clearance, the agency also sanctioned the firm's new software, called RAPID 3, which includes a number of features and enhancements. The clearance allows the firm to receive the first milestone payment from Ethicon Endo-Surgery amounting to $10m, said the Yoqneam Israel company. This amount will be recorded on a straight line over the 15-year life of the agreement as a reduction in marketing expenses.

You may also be interested in...



ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

Topics

UsernamePublicRestriction

Register

MT060330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel